Innovent Announces the Appointment of Dr. Yong Jun Liu as the President of the Group

SAN FRANCISCO and SUZHOU, China, Oct. 15, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today announces the appointment of Dr. Yong Jun Liu, a renowned world class scientist and successful leader in biopharmaceutical industry, as the president of the group. Reporting to Dr. Michael Yu, founder, chairman and CEO of the group, Dr. Liu will be mainly responsible for group's global R&D, portfolio strategy, business development as well as international operation.

As a world renowned scientist in immunology, oncology and translational medicine, Dr. Liu has over 30 years' experiences in both academic institutions and top global pharmaceutical companies. Dr. Liu received his MD's degree in internal medicine from Bethune Medical University in 1984 and Ph.D. degree in Immunology from University of Birmingham, UK in 1989. After two years postgraduate training in the same laboratory at University of Birmingham, he joined multinational pharmaceutical company Schering-Plough in 1991 as a Senior Scientist at Schering-Plough Lyon France. In 1997, he moved to the DNAX Research Institute, a biotech company owned by Schering-Plough in Palo Alto, California, as a Principal Staff Member. In 2002, Dr. Liu was recruited by the University of Texas (UT), MD Anderson Cancer Center, as the Vivian Smith Distinguished Chair Professor, Chairman of the Department of Immunology and the founding Director of the Center for Cancer Immunology Research (CCIR). In 2011, Dr. Liu was recruited by the Baylor Research Institute as the Chief Scientific Officer and the Director of the Baylor Immunology Research Institute. After more than 10 years at the academia, Dr. Liu was recruited by Medimmune, a biopharmaceutical subsidiary of AstraZeneca, as Chief Scientific Officer and global Head of Research in 2014. Before joining Innovent, Dr Liu served as the global Head of Research at Sanofi from 2016 to 2020.

Dr. Liu has remarkable academic achievements and rich experience in research institutions. As one of the top cited scientists in Immunology with over 94,000 citations, Dr. Liu published over 260 scientific papers in Nature, Science and other top academic journals. These studies provide a number of key targets for drug development in the area of inflammation, autoimmune diseases, allergy and oncology, such as thymic stromal lymphopoietin (TSLP), OX40 (CD134), plasma cell like dendritic cells (pDCs).

As key executive R&D leader in multiple global pharmaceutical companies for nearly a decade, Dr. Liu has made remarkable achievements in strengthening drug research capability and enriching early stage innovative pipelines in major therapeutic areas, especially in the fields of immunology and oncology. His leadership skill and strategic thinking guided R&D functions to effectively develop first-in-class and best-in-class drugs during his tenure in various global pharmaceutical companies.

"Warmly welcome Dr. Liu and we are more than excited to have him join Innovent," said Dr. Michael Yu, founder, chairman and CEO of Innovent. "Dr. Liu is not only a renowned scientist with strong academic background but also a powerful manager with extraordinary leadership and rich experience in drug research and development. His successful experience in strengthening the drug research capability and enriching innovative pipeline is an ideal fit to Innovent's strategic goal of developing a first-in-class pipeline for the global market. We believe that Dr. Liu's leadership will bring added benefits to further strengthen our R&D capability and solidify our efforts in building a global R&D platform and developing a more innovative pipeline."

"Innovent is a rapid growing and innovative biopharmaceutical company," said Dr. Liu. "I'm very pleased to join such a company with strong emphases on science and innovation, high execution capability and so many talented and passionate people. I look forward to working with our global team to develop innovative life changing medicine that benefit patients of the world."

About Innovent

Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to develop and commercialize high quality biopharmaceutical products that are affordable to ordinary people. Established in 2011, Innovent is committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of cancer, metabolic, autoimmune and other major diseases. On October 31, 2018, Innovent was listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK.

Since its inception, Innovent has developed a fully-integrated multi-functional platform which includes R&D, CMC (Chemistry, Manufacturing, and Controls), clinical development and commercialization capabilities. Leveraging the platform, the company has built a robust pipeline of 23 valuable assets in the fields of cancer, metabolic, autoimmune diseases and other major therapeutic areas, with four products, TYVYT® (sintilimab injection), BYVASDA® (bevacizumab injection), SULINNO® (adalimumab injection), HALPRYZA® (rituximab injection) officially approved for marketing in China, four assets in Phase III or pivotal clinical trials, and additional 15 molecules in clinical trials. TYVYT® has been the only PD-1 inhibitor included in the NRDL since 2019.

Innovent has built an international team with expertise in cutting-edge biological drug development and commercialization. The company has also entered into strategic collaborations with Eli Lilly, Roche, Adimab, Incyte, MD Anderson Cancer Center, Hanmi and other international partners. For more information, please visit:

Related Links :

Look out for further updates on our Facebook fan page!

Related Articles

  • 【職場熱話】扮孫悟空被餵食5小時 網民:最理想工作!下個月可以扮OOO!


  • 【職場測驗】Fresh Grad搵工必睇!10條問題測出你最適合入邊行

    俗語有云「女怕嫁錯郎,男怕入錯行」,對於準備投身社會的Fresh Grad來說,現在最重要的是認清楚的求職方向,為未來的事業發展打下良好基礎。如果你正處於搵工迷惘階段,不妨回答以下心理測驗的10條問題,再將分數加起來,看看自己最適合從事哪個行業吧!

  • 【政府工略】民政署時薪$120請助理 負責社區強制檢測


  • 【行業辛酸】12碼保安大呻返工日日被監視 業主計時巡樓、限時去廁所、唔畀㩒電話


  • 【政府工略】律政司請法律書記 中學畢業月薪$21,340

    有關法律的工作,一般人以為必定要有法律背景的求職者,方能合資格申請。不過,律政司招聘的政府工 — 合約法律書記,不需要任何法律背景,只要符合以下入職條件即可報名,月薪$21,340。

  • 【職場熱話】移民澳洲太輕鬆竟然唔適應? 打工仔:係咪做奴工做得太耐?


  • 【職場熱話】人工得8千但返工好開心 員工:每日淨係數鉛筆、冇是非


  • 【政府工略】消防處請辦公室經理 兼職時薪$352


  • 【職場熱話】少年推銷員被保安阿叔叫「阿叔」 大怒:我係阿叔你咪係OO?


  • 【政府工略】海事處公開招聘驗船主任 月薪$74,515點先做到?

    海事處最近公開招聘多個職位,包括驗船主任、助理驗船主任、海事主任及助理海事主任,讓合資格的海事人才投考。首輪招聘的空缺是驗船主任,以政府公務員條款聘用,月薪由總薪級表第34點 ($74,515) 至第44點 ($110,170),只要符合以下的入職條件,即可於2021年5月14日前遞交申請表格。按圖了解各職位詳情︰